154 completed, 18 terminated, 12 recruiting, 9 withdrawn. 204 Phase 2, 27 Phase 1, 25 Phase 3.
Follow Tobacco Use Disorder: new trials by email Literature Review of Tobacco Use Disorder trials Research Report on Tobacco Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Psilocybin on Craving in Nicotine Dependence Psilocybin (drug) - Nicotine Dependence | Phase 2 | Not yet recruiting | University of British Columbia | 3 | 2027-01-01 | 2026-10-01 |
| THCV Treatment for Smokers Δ9-Tetrahydrocannabivarin (oral gummy), Matched Placebo (oral gummy) - Tobacco Use Disorder, Smoking Cessation | Phase 2 | Not yet recruiting | University of California, Los Angeles | 32 | 2026-10-01 | 2026-08-04 |
| A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation Non-invasive vagus nerve stimulator plus nicotine replacement patches, nicotine replacement patches - Smoking Cessation | Phase 2 / Phase 3 | Recruiting | Mayo Clinic | 150 | 2026-06-04 | 2026-09-25 |
| Accelerated dTMS Smoking Cessation Bilateral deep accelerated repetitive transcranial magnetic stimulation - Tobacco Use Disorder, Addiction Nicotine | Phase 2 | Recruiting | Waypoint Centre for Mental Health Care | 40 | 2026-02-24 | 2026-04-21 |
| The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction VapeAway filter system - Addiction Nicotine | Phase 2 | Recruiting | VapeAway | 70 | 2025-12-24 | 2026-01-07 |
| A Trial of Varenicline for E-cigarette Cessation Varenicline 1mg BID, Placebo - E-cigarette Use, Vaping | Phase 2 | Recruiting | Yale University | 326 | 2025-10-14 | 2025-12-17 |
| Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 Varenicline - Alcohol Use Disorder, Hiv | Phase 2 | Terminated | Yale University | 3 | 2025-06-16 | 2026-11-06 |
| Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity Cytisinicline, Placebo Oral Capsule - Smoking Cessation, Tobacco Use Disorder | Phase 2 | Recruiting | University of California, Los Angeles | 64 | 2024-12-05 | 2025-12-03 |
| Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes Varying the nicotine content of cigarettes, Varying the nicotine content of e-cigarettes - Tobacco Use Disorder | Phase 2 | Recruiting | University of Vermont | 308 | 2024-11-01 | 2025-06-27 |
| Cannabidiol for Reducing Cigarette Use Cannabidiol (CBD) 800 mg, Placebo - Tobacco Use Disorder, Tobacco Smoking | Phase 2 | Recruiting | University of California, Los Angeles | 120 | 2024-10-31 | 2026-04-13 |
| The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence Placebo, AB-free kava - Smoking | Phase 2 | Recruiting | University of Florida | 76 | 2024-06-06 | 2026-01-27 |
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder Psilocybin, Niacin - Tobacco Use Disorder | Phase 2 | Recruiting | Johns Hopkins University | 66 | 2023-11-01 | 2026-06-29 |
| Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD active repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation, cognitive behavioral therapy for smoking cessation - Tobacco Use Disorder | Phase 2 | Recruiting | VA Office of Research and Development | 50 | 2023-10-31 | 2026-02-18 |
| Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans Varenicline, Placebo - Tobacco Use Disorder, Cannabis Use Disorder | Phase 2 | Withdrawn | VA Office of Research and Development | 2023-04-17 | 2024-08-27 | |
| Overcoming Nicotine Dependence to Enable Quitting Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling - Tobacco Use, Smoking Cessation | Phase 1 / Phase 2 | Recruiting | Rush University Medical Center | 780 | 2023-03-24 | 2026-09-09 |
| Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO) NFL-101, Placebo - Smoking Cessation, Nicotine Dependence | Phase 2 | Completed | NFL Biosciences SAS | 34 | 2023-02-21 | 2023-10-19 |
| Effects of Semaglutide on Nicotine Intake Semaglutide, Sham/placebo - Tobacco Use Disorder, Nicotine Addiction | Phase 2 | Completed | University of North Carolina, Chapel Hill | 24 | 2022-10-07 | 2025-08-22 |
| Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking Contingency Management, Non-contingent control - Alcohol Use Disorder (AUD), Nicotine Use Disorder | Phase 2 | Recruiting | Washington State University | 205 | 2022-07-11 | 2026-07-06 |
| Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava Kava, Placebo - Smoking | Phase 2 | Terminated | University of Florida | 19 | 2022-06-09 | 2026-09-03 |
| Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties Coaching calls, Nicotine replacement therapy, Financial Incentives - Cigarette Smoking, Nicotine Dependence | Phase 2 | Completed | University of Oklahoma | 165 | 2022-03-09 | 2024-12-30 |
Showing 20 of 204. Sign in to see all of them.
Smoking Cessation (56) · Smoking (46) · Cigarette Smoking (18) · Alcoholism (12) · Tobacco Use (10) · Tobacco Use Cessation (10) · Vaping (10) · Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (7) · Schizophrenia (7) · Body Weight (4) · Small Cell Lung Carcinoma (4) · Behavior, Addictive (3) · Harm Reduction (3)
Chemically-Induced Disorders (204) · Mental Disorders (204) · Substance-Related Disorders (201) · Behavior (118) · Health Behavior (65) · Smoking (28) · Tobacco Use (21) · Tobacco Smoking (18) · Alcohol-Related Disorders (10) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Neoplasms (9) · Neoplasms by Site (9) · Pathological Conditions, Signs and Symptoms (9) · Respiratory Tract Neoplasms (9)
Tobacco Use Cessation Devices (31) · Varenicline (27) · Bupropion (18) · Nicotine (17) · Nicotine Replacement Therapy (10) · Behavior Therapy (9) · Sugars (9) · Nicotine Chewing Gum (7) · Electronic Nicotine Delivery Systems (6) · Naltrexone (6) · Acetylcysteine (4) · Cognitive Behavioral Therapy (4) · Counseling (4) · Tobacco Products (4) · Aspirin (3)
National Institute on Drug Abuse (NIDA) (27) · Yale University (14) · University of Pennsylvania (13) · Brown University (11) · Mayo Clinic (11) · University of Vermont (10) · Duke University (8) · University of Minnesota (8) · Centre for Addiction and Mental Health (7) · Medical University of South Carolina (7) · National Cancer Institute (NCI) (6) · University of California, Los Angeles (4) · VA Office of Research and Development (4) · Johns Hopkins University (3) · University of Florida (3)
United States (177) · Canada (10) · France (3) · Denmark (2) · Australia (1) · Germany (1) · India (1) · Italy (1) · South Africa (1) · Sweden (1)
Dorothy Hatsukami, Ph.D. (9) · Jed E Rose, Ph.D. (6) · Dorothy Hatsukami, PhD (5) · Jennifer Tidey, Ph.D. (4) · Jennifer W. Tidey (3) · Rebecca Ashare, Ph.D. (3) · Bernard Le Foll, MD, PhD (2) · Caryn Lerman, Ph.D. (2) · Caryn Lerman, PhD (2) · Eric T. Moolchan, M.D. (2) · James M Davis, M.D. (2) · Jed E. Rose, Ph.D. (2) · John R Hughes, MD (2) · John R. Knight, MD (2) · Jon O Ebbert, MD (2)
PMID 37230961, PMID 37142273, PMID 42560883, PMID 32628945, PMID 33079196, PMID 34242666, PMID 34255068, PMID 36208817, PMID 38236223, PMID 25192771, PMID 33605440, PMID 39240566, PMID 16960700, PMID 17587504, PMID 18096137, PMID 18381502, PMID 18827129, PMID 18837602, PMID 19339135, PMID 20056957, PMID 20078491, PMID 20542391, PMID 20590478, PMID 20707784, PMID 20934835, PMID 20947286, PMID 21221531, PMID 21276244, PMID 21475970, PMID 21652735, PMID 21762878, PMID 21846661, PMID 22007015, PMID 22097928, PMID 22160487, PMID 22197799, PMID 22218402, PMID 22352784, PMID 22452559, PMID 22464727, PMID 22993168, PMID 23024246, PMID 23261228, PMID 23429725, PMID 23454876, PMID 23460656, PMID 23536105, PMID 23586456, PMID 23603206, PMID 23873976
P50DA027840 (6), P50AA015632 (4), P50DA036114 (3), U54DA036114 (3), K01DA019446 (2), N01CN00031 (2), P01CA096964 (2), P30CA023074 (2), P50DA013333 (2), U01DA019378 (2), 1RC1DA028279-01 (1), 2005 (1), I01CX002357 (1), K01MD015295 (1), K23DA019950 (1)